Clinical-radiomics hybrid modeling outperforms conventional models: machine learning enhances stratification of adverse prognostic features in prostate cancer

临床放射组学混合模型优于传统模型:机器学习增强了前列腺癌不良预后特征的分层能力

阅读:1

Abstract

OBJECTIVE: This study aimed to develop MRI-based radiomics machine learning models for predicting adverse pathological prognostic features in prostate cancer and to explore the feasibility of integrating radiomics with clinical characteristics to improve preoperative risk stratification, addressing the limitations of conventional clinical models. METHODS: A retrospective cohort of 137 prostate cancer patients between January 2021 and April 2023 with preoperative MRI and postoperative pathology data was divided into adverse-feature-positive (n=85) and negative (n=52) groups. Regions of interest (ROIs) were delineated on ADC and T2WI sequences, and 31 radiomics features were extracted using PyRadiomics. LASSO regression selected optimal features, followed by model construction via five algorithms (logistic regression, decision tree, random forest, SVM, AdaBoost). Clinical models incorporated three variables: biopsy Gleason grade, total PSA, and prostate volume. The best-performing radiomics model was combined with clinical features to build a hybrid model. Model performance was evaluated by AUC, sensitivity, specificity, accuracy, calibration curves, and decision curve analysis (DCA). RESULTS: Patients were randomly split into training (n=95) and validation (n=42) cohorts. The random forest model using ADC-T2WI combined features achieved the highest AUC (0.832; 95% CI: 0.706-0.958) in the validation set, outperforming the clinical model (AUC=0.772). The hybrid model demonstrated superior performance (AUC=0.909; 95% CI: 0.822-0.995), with sensitivity=0.813, specificity=0.885, and accuracy=0.857. Calibration and DCA confirmed its robust clinical utility (p<0.01 vs. single models). CONCLUSIONS: The biparametric MRI radiomics-random forest model effectively predicts adverse pathological features in prostate cancer. Integration with clinical characteristics further enhances predictive accuracy, offering a non-invasive tool for preoperative risk stratification and personalized treatment planning.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。